Treatment for HOCM.

Reading File

Finding Sources

Searching PubMed

hypertrophic obstructive cardiomyopathy treatment

Searching the Web

HOCM treatment guidelines 2024 2025

Finding Sources

Reading Web Page

HOCM treatment obstructive hypertrophic cardiomyopathy management

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive information from Harrison's 22E (2025) and the 2024 AHA/ACC guideline context. Here is the full answer:

Treatment of HOCM (Hypertrophic Obstructive Cardiomyopathy)

Treatment algorithm for HCM based on symptoms and outflow gradient - Harrison's Principles of Internal Medicine 22E

General Principles

All patients with HOCM should be evaluated for:

Risk of sudden cardiac death (SCD) - regardless of symptoms
Symptomatic status - guides step-up therapy
Atrial fibrillation - common complication requiring specific management

1. Medical Management

First-Line: Negative Chronotropes/Inotropes

Drug Class	Agents	Mechanism
Non-vasodilating beta-blockers	Metoprolol, atenolol, propranolol	Slow HR, reduce contractility, enhance diastolic filling
Calcium channel blockers (L-type)	Verapamil	Slow HR, reduce obstruction

These reduce LVOT obstruction by decreasing HR (lengthening diastolic filling time) and reducing contractility.
Avoid vasodilators (nitrates, ACE inhibitors, dihydropyridine CCBs) - they worsen obstruction by reducing preload/afterload.

Second-Line: Persistent Symptoms with Outflow Gradient

Disopyramide - a class IA antiarrhythmic with potent negative inotropic properties. Add to a beta-blocker or verapamil when symptoms persist despite first-line therapy.

Novel Agent: Cardiac Myosin Inhibitor

Mavacamten (FDA-approved, 2022) - a first-in-class small-molecule cardiac myosin inhibitor that directly targets the pathophysiologic mechanism of HCM (hypercontractility). Indicated for symptomatic obstructive HCM, including patients with persistent symptoms despite beta-blocker and/or disopyramide therapy. A 2025 meta-analysis confirmed its high efficacy at reducing LVOT gradients and improving symptoms (PMID: 39988344).

Aficamten is another cardiac myosin inhibitor under active investigation showing similar efficacy.

2024 AHA/ACC guideline update (reaffirmed May 2025): Mavacamten is now formally positioned in the treatment algorithm for symptomatic obstructive HCM. The guideline was reaffirmed as current.

Diuretics

For patients with fluid retention/venous congestion (with or without obstruction), cautious use of diuretics is appropriate - but avoid hypovolemia, which worsens LVOT obstruction.

2. Septal Reduction Therapy (SRT)

Reserved for ~5% of patients with severe, medically refractory symptoms. Both procedures are roughly equivalent in gradient reduction.

A. Surgical Septal Myectomy (Morrow Procedure)

Gold standard, developed 60+ years ago
Excises part of the septal myocardium causing dynamic obstruction
Perioperative mortality is very low at experienced centers
Excellent long-term survival free of recurrent obstruction
Mitral regurgitation (due to SAM) usually resolves without separate MV repair
Preferred for younger patients, those with complex anatomy, or concomitant cardiac lesions

B. Alcohol Septal Ablation (ASA)

Controlled infarction of the proximal septum via selective injection of ethanol into a septal perforator artery
Requires suitable coronary anatomy (a large septal perforator)
Comparable peri-procedural outcomes and gradient reduction to myectomy
Reserved for patients who wish to avoid surgery or have significant comorbidities
Common complication of both SRT: Complete heart block requiring permanent pacemaker

Note: Ventricular pacing alone as primary therapy for obstruction is ineffective and not recommended.

3. Prevention of Sudden Cardiac Death

SCD risk is ~0.5%/year baseline. ICD implantation is indicated for:

Class I (definite): Prior cardiac arrest or sustained VT
Class IIa (reasonable): 1+ major risk factors (see below)

Major SCD risk factors:

Prior cardiac arrest or sustained VT
Unexplained syncope (especially exertional)
Family history of SCD
LV wall thickness >30 mm
LV apical aneurysm
LV systolic dysfunction (EF <50%)

The ESC HCM Risk-SCD calculator (continuous variables: LVOT gradient, LA diameter, max wall thickness, age, syncope, family history, NSVT) gives a 5-year risk estimate:

≥6%: ICD generally advised
4-6%: ICD may be considered
<4%: ICD not advised

4. Atrial Fibrillation Management

Rate control: beta-blockers, verapamil, or diltiazem
Rhythm control: disopyramide + rate-control agent, or amiodarone
Anticoagulation: Recommended for stroke prevention (HCM patients are at elevated thromboembolic risk regardless of CHA₂DS₂-VASc score)

5. Lifestyle Considerations

Historically, vigorous exercise and competitive sports were prohibited. However, recent data have not identified a clear link between exertion and ventricular arrhythmias in HCM, and the 2024 AHA/ACC guideline supports shared decision-making about activity levels rather than blanket restriction.

What to Avoid in HOCM

Drug/Intervention	Reason
Nitrates, hydralazine	Reduce preload → worsen obstruction
Dihydropyridine CCBs (nifedipine, amlodipine)	Vasodilation → worsen obstruction
Digoxin	Positive inotropy → worsen obstruction
High-dose diuretics	Hypovolemia → worsen obstruction
Vasopressors (dopamine/dobutamine)	Inotropic, worsen obstruction

Sources: Harrison's Principles of Internal Medicine 22E (2025), p. 2051; 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for Management of HCM (reaffirmed May 2025); Aman A et al., Open Heart 2025 (PMID 39988344) - systematic review of mavacamten/aficamten.

This is a shared conversation. Sign in to Orris to start your own chat.